N.J. Admin. Code § 13:39-13.3 - Board approval; pharmacist qualifications; continuing education
(a) In
order to enter into an agreement to engage in the collaborative drug therapy
management of a patient with a physician licensed in this State, a licensed
pharmacist shall be pre-approved by the Board to engage in such activity. In
order to obtain Board approval, a pharmacist shall submit a collaborative
practice application and documentation that establishes that he or she has
successfully completed one of the following:
1. A certificate training program offered by
an Accreditation Council for Pharmacy Education (ACPE)-approved
provider;
2. A post-graduate
residency program accredited by the American Society of Health-System
Pharmacists; or
3. A certification
program from the Board of Pharmacy Specialties.
(b) The Board shall issue an authorization to
engage in collaborative drug therapy management to a pharmacist who, upon
application to the Board, demonstrates satisfaction of the requirements of (a)
above.
(c) A pharmacist granted
authorization to engage in collaborative drug therapy management pursuant to
this section shall complete a minimum of 10 credits of continuing education
every biennial renewal period in each disease(s) or condition(s) covered by the
collaborative practice agreement(s) to which he or she is a party, consistent
with the requirements of N.J.A.C. 13:39-3A. However, to the extent that a
pharmacist may enter into collaborative practice agreements to treat patients
with co-existing, interrelated conditions or diseases, a pharmacist need only
complete a total of 10 credits in the interrelated conditions or
diseases.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.